CDSCO nod to ENTOD Pharma new eye drop to slow Myopia progression in children

The Central Drugs Standard Control Organisation (CDSCO) granted marketing authorisation following the successful completion of a Phase 3 clinical trial conducted across 11 sites in India. The approval comes after a rigorous evaluation process by India’s apex drug regulator, further underscoring the robustness and credibility of the scientific data generated by ENTOD Pharmaceuticals’ research team.

Commenting on the CDSCO’s marketing approval, Mr. Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals, stated, "This is a proud moment for our research and regulatory teams. Securing regulatory approval for this unique treatment strength—the first of its kind globally—underscores our continued commitment to innovation in eye care. With myopia rates in India rising from 4% in 1999 to nearly 25% today, and projections suggesting that by 2050 one in two children could be affected, the need for such a therapy has never been more urgent.